The Administration for Strategic Preparedness and Response March 24 announced an investment to expand the domestic manufacturing of propofol and metoprolol. Propofol is a sedative used for anesthesia and intensive care unit sedation, while metoprolol is a medication used to treat cardiovascular conditions such as arrhythmias and hypertension, and can also reduce lung inflammation in ICU settings. ASPR said the API Innovation Center, based in St. Louis, was awarded $8.3 million to produce both ingredients. The investment is the latest in a series of projects by ASPR and the Department of Health and Human Services to reduce reliance on foreign resources and increase the domestic production of essential medications and their active pharmaceutical ingredients.

Headline
The Administration for Strategic Preparedness and Response announced Nov. 3 that it will partner with the Bureau of Industry and Security and the Assistant…
Headline
The Department of Health and Human Services Sept. 18 announced the launch of a new personal protective equipment forecast to identify, consolidate and publish…
Headline
The Centers for Medicare & Medicaid Services’ six-month moratorium on the enrollment of new durable medical equipment, prosthetics, orthotics and supply…
Headline
The U.S. Trade Representative yesterday announced it is implementing a 10% or 12.5% tariff on 60 trading partners, which became effective today. These…
Headline
The Food and Drug Administration July 10 released a proposed rule that would modernize drug establishment registration requirements, with implications for…
Headline
The AHA today sent a letter to the Office of the United States Trade Representative to ask that medications, medical devices and other healthcare…